A Philadelphia judge said an appeal by Wyeth Pharmaceuticals of her decision not to dismiss digestive drug products liability claims filed against the drugmaker at the preliminary objections stage should be quashed.
Around 2,000 plaintiffs have filed lawsuits against Wyeth, which is owned by Pfizer, as well as several other defendant drugmakers alleging that their use of metoclopramide caused them to have an incurable neurological disorder called tardive dyskinesia, according to court papers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
